Pfizer vs. Merck Stock And JNJ

Core Insights - Pfizer's stock has underperformed compared to Merck and Johnson & Johnson due to declining demand for COVID-19 products, an impending patent cliff, and a weak financial outlook for 2026 [2][3] - In contrast, Merck and Johnson & Johnson have demonstrated steady growth supported by strong existing portfolios and promising pipelines [3] Financial Performance - Pfizer's operating margin stands at 24.6%, which, while substantial, is lower than Eli Lilly's 43.0%, indicating differences in product mix profitability or cost structures [7] - Pfizer's revenue growth is at 3.9%, which lags behind Johnson & Johnson, AbbVie, and Eli Lilly, suggesting challenges in its pipeline or the impact of patent expirations, although it surpasses Merck and Bristol-Myers Squibb [7] - The stock price of Pfizer has increased by 6.4%, with a price-to-earnings (P/E) ratio of 15.0, which is lower than those of Johnson & Johnson, Merck, AbbVie, and Eli Lilly, reflecting investor skepticism regarding future growth or pipeline strength [7] Competitive Landscape - An in-depth examination reveals that Pfizer exhibits moderate profitability and growth, along with a competitive valuation, but faces limitations due to the rapid advancement of biotech and specialty pharma companies [3]